<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To evaluate the role of non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> and <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> (apo)B, markers of <z:hpo ids='HP_0000001'>all</z:hpo> potentially atherogenic <z:chebi fb="2" ids="6495">lipoproteins</z:chebi>, as predictors of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) in comparison with <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: We prospectively followed 746 diabetic men in the Health Professionals' Follow-up Study who were aged 46-81 years and free of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> or <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> at the time of blood draw in 1993-1994 </plain></SENT>
<SENT sid="2" pm="."><plain>During 6 years of follow-up, we ascertained 103 incident <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> cases </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: We used Cox proportional hazard modeling to estimate the relative risk (RR) of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>After adjustment for age, BMI, and other lifestyle risk factors, the multivariate RR of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> (the highest versus the lowest quartile) was 2.34 (95% CI 1.26-4.32) for non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi>, 2.31 (1.23-4.35) for apoB, and 1.74 (0.99-3.06) for <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Comparisons of nested models indicate that non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi>, but not apoB, adds significantly to the prediction of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk beyond <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>The area under the receiver operating characteristic curve was 0.685, 0.691, 0.695, and 0.722 for the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk-prediction model with <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi>, apoB, non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi>, and total cholesterol-to-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> ratio (or the non-<z:chebi fb="17" ids="39025">HDL</z:chebi>-to-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> ratio), respectively </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> and apoB are more potent predictors of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> incidence among diabetic men than <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>Statistically, the ratio of total to <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> is the best predictor of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> in this cohort of diabetic men </plain></SENT>
</text></document>